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Background: We provide an up-to-date international comparison of cancer survival, assessing whether England is ‘closing the
gap’ compared with other high-income countries.
Methods: Net survival was estimated using national, population-based, cancer registrations for 1.9 million patients diagnosed
with a cancer of the stomach, colon, rectum, lung, breast (women) or ovary in England during 1995–2012. Trends during 1995–2009
were compared with estimates for Australia, Canada, Denmark, Norway and Sweden. Clinicians were interviewed to help interpret
trends.
Results: Survival from all cancers remained lower in England than in Australia, Canada, Norway and Sweden by 2005–2009.
For some cancers, survival improved more in England than in other countries between 1995–1999 and 2005–2009; for example,
1-year survival from stomach, rectal, lung, breast and ovarian cancers improved more than in Australia and Canada. There has
been acceleration in lung cancer survival improvement in England recently, with average annual improvement in 1-year survival
rising to 2% during 2010–2012. Survival improved more in Denmark than in England for rectal and lung cancers between 1995–
1999 and 2005–2009.
Conclusions: Survival has increased in England since the mid-1990s in the context of strategic reform in cancer control, however,
survival remains lower than in comparable developed countries and continued investment is needed to close the international
survival gap.
The gap in cancer survival between England and comparable
countries has galvanised policymakers and clinicians since EURO-
CARE first launched its European survival comparisons (Berrino
et al, 1995). Evidence that survival is generally lower in England has
led to target setting and increased investment, aiming to raise survival
in England to the standards achieved elsewhere.
Since the Calman–Hine Report recommended strategic
improvements to cancer services in England, there has been a
series of policy initiatives to improve survival (Expert Advisory
Group on Cancer, 1995). The NHS Cancer Plan for England
(Department of Health, 2000) was the second national cancer plan
in the world (following Norway’s). It emphasised centralisation,
specialisation and use of multi-disciplinary teams (MDTs).
A further suite of measures to improve prevention, earlier
diagnosis and patient management was launched through the
Cancer Reform Strategy (Department of Health, 2007) to address
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continuing concerns about the survival deficit in comparison to
other high-income countries.
In 2009, the Department of Health in England formed the
International Cancer Benchmarking Partnership (ICBP), a con-
sortium of epidemiologists, clinicians and policymakers tasked
with understanding survival differences between the United
Kingdom and five other high-income countries with universal
healthcare system coverage: Australia, Canada, Denmark, Norway
and Sweden. The ICBP demonstrated steady improvement in
survival from colorectal, lung, breast and ovarian cancers in all six
countries for patients diagnosed during 1995–2007, but showed
that survival in the United Kingdom and Denmark was
consistently lower than elsewhere, and there was no evidence of
‘catch-up’ with the other countries, with the exception of breast
cancer (Coleman et al, 2011).
‘Closing the gap’ therefore remains an on-going focus for UK
health policy. At the time of publication of a new national cancer
strategy for England, this paper uses the most up-to-date data
available to ask whether England is now closing the international
gap in cancer survival. Given the influence of the ICBP in defining
the recent cancer policy agenda in England, we include the same
cancers and countries as that study, with the addition of stomach
cancer. We assess progress in a variety of ways, considering both
the absolute ‘gap’ and relative improvement over time.
MATERIALS AND METHODS
Patients. Individual cancer registrations for 1.9 million adults
(aged 15–99 years) diagnosed with a cancer of the stomach, colon,
rectum, lung, breast (women) or ovary in England during 1995–
2012, and followed up to 31 December 2013 were obtained from
the National Cancer Registry at the Office for National Statistics,
linked to the National Health Service Central Register for
information on the eventual death of these patients. Cancer
registration is a live process, with continual updating of historic
registrations, and the current data set was extracted on 22 May
2014.
One- and five-year survival estimates for a further 1.9 million
patients diagnosed with one of these six cancers in Australia,
Canada, Denmark, Norway or Sweden during 1995–2009, and
followed up to 31 December 2009, were extracted from the
CONCORD-2 study (Allemani et al, 2015). The CONCORD
programme, based at the London School of Hygiene and Tropical
Medicine, conducts global surveillance of cancer survival using
data from population-based cancer registries. The CONCORD-2
study comprised analysis of individual data for 25.7 million adults
(aged 15–99 years) diagnosed with any of ten cancers, and 75 000
children diagnosed with childhood acute lymphoblastic leukaemia,
from 279 cancer registries in 67 countries.
Whereas the ICBP data were national for Denmark, Norway
and the United Kingdom, here the coverage is national for
England, Sweden (cf. 43% coverage in ICBP), Canada (cf. 65%),
Denmark and Norway, and 91% for Australia (cf. 60%).
The same inclusion criteria were applied to the National Cancer
Registry data for England as to the CONCORD-2 data (Allemani
et al, 2015). Patients diagnosed with an invasive, primary,
malignant neoplasm of one of the specified sites were eligible for
analysis, and they were excluded if their tumour was benign (not
malignant) or in situ (malignant but not invasive) or of uncertain
behaviour (uncertain whether benign or malignant), or if the organ
of origin was unknown. If a patient was diagnosed with two
invasive primary tumours at different sites, both tumours were
included. If a patient was diagnosed with two primary tumours at
the same site, only the first tumour was considered. Patients whose
tumour was registered through death certification only were
excluded (data quality control statistics by cancer site in
Supplementary Webtables 1–6).
The CONCORD-2 topographical definition of tumour sites was
applied using the International Classification of Diseases for
Oncology (3rd Edition; ICD-O-3). This diverges slightly from the
specification used in the production of National Statistics on
cancer in England (details available on request; Table 1).
Methods. Methods and tools used in the CONCORD-2 study
were applied to the more up-to-date National Cancer Registry data
for England in order to compare cancer survival in all six countries
for the calendar periods of diagnosis 1995–1999, 2000–2004 and
2005–2009. Survival was also estimated for patients diagnosed
during 2010–2012 in England, as well as year-on-year trends for
1995–2012, with follow-up to 2013 (Figure 1).
Cancer patients can die from causes other than their cancer. We
estimated net survival, which represents survival in the hypothe-
tical scenario that the cancer in question is the only possible cause
of death, factoring out mortality from other causes. This
background mortality was estimated using life tables of all-cause
mortality rates in the population. We used the same life tables for
England as were used in the CONCORD-2 analyses, which were
specific to single year of age, calendar year, sex and Government
Office Region. To estimate net survival, we used the Stata tool stns
(Clerc-Urme`s et al, 2014), which implements the Pohar–Perme
estimator (Pohar Perme et al, 2012). It takes into account how
competing risks of death from other causes increase with age.
One- and five-year net survival were estimated using the
traditional cohort method for the periods of diagnosis 1995–1999
and 2000–2004. To estimate 1- and 5-year net survival using a
cohort approach, it is necessary to have the potential of 1 or 5 full
years of follow-up, respectively, for each patient, which was not the
case for patients diagnosed in 2005–2009 in the CONCORD-2
study. A period approach was therefore used for these patients
(Brenner and Gefeller, 1996). For comparability, we also used
period analysis for the calendar period 2005–2009 in England, even
though we did have enough follow-up data to estimate 1-year
survival for these patients. For patients diagnosed in England in
2010–2012, we used cohort analysis to estimate 1-year net survival,
and a period approach was needed to estimate 5-year net survival
(see Supplementary Webfigures 1 and 2 for structure of survival
analyses for 1-year and 5-year survival by calendar period).
Year-on-year trends in England for patients diagnosed during
1995–2012, with follow-up to the end of 2013 were estimated using
a cohort approach for 1-year net survival. Cohort analysis was also
used to estimate 5-year net survival for patients diagnosed up to
2008, and a hybrid approach was used to predict survival at 5 years
in 2013 (Brenner and Rachet, 2004) (see Supplementary
Webfigures 3 and 4 for structure of year-on-year analyses of 1-
year and 5-year survival).
Net survival from cancer varies by age, so apparent differences
in overall survival between two cancer patient populations can be
driven by underlying differences in the age distributions of those
populations. To limit this potential bias, we present age-
standardised estimates of net survival, using the same age weights
as employed in the CONCORD-2 analyses to enable comparison.
These were the International Cancer Survival Standard (ICSS)
weights, for which age at diagnosis was categorised into five
groups: 15–44 years, 45–54 years, 55–64 years, 65–74 years and
75–99 years (Corazziari et al, 2004).
To assess whether or not England had ‘closed the gap’ in cancer
survival, we interrogated the results in three ways. First, we
assessed whether survival for patients diagnosed in 2005–2009 in
England equalled or exceeded that in the other countries: where
survival was higher in England, or where the 95% confidence
interval for the difference between the two-point estimates
included zero, we considered England to have ‘caught up’ with
Is England closing the gap in survival? BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.265 849
the other country. Second, we asked whether survival in England
by 2010–2012 had ‘caught up’ with the level observed in each other
country in 2005–2009. Third, we assessed whether survival in
England had improved more than elsewhere during 1995–2009,
even if ‘catch-up’ had not yet been achieved, by considering the
confidence intervals for the difference in improvement between
England and each other country. To do this, we calculated how
much survival had improved in each other country between 1995–
1999 and 2005–2009 and compared this to the amount of
improvement in England. We report on these differences with
reference to their 95% confidence intervals; the difference in
improvements between England and the other country was
considered statistically significant at the 5% level if the confidence
interval for the difference did not include zero.
Table 1. Number of patients available for analysis by calendar period of diagnosis, cancer site and country
Stomach Colona Rectumb Lungc Breast Ovaryd All cancers
Cancer and ICD-O-
3 topography code
C16.0-C16.6,
C16.8-C16.9
C18.0-C18.9,
C19.9
C20, C21.0-
C21.2, C21.8
C34.0-C34.3,
C34.8-C34.9
C50.0-C50.6,
C50.8-C50.9
C48.0-C48.2, C56.9,
C57.0-C57.4, C57.7-C57.9
Australia
1995–1999 8293 37303 13695 35 186 47 487 5485 147449
2000–2004 8643 41803 16498 38 751 55 000 6188 166883
2005–2009 6885 35672 13959 34 088 46 146 5226 141976
1995–2009 23 821 114778 44152 108 025 148 633 16899 456308
Canada
1995–1999 14 218 55969 12538 92 176 86 819 7253 268973
2000–2004 14 555 65354 15421 101 386 95 308 7717 299741
2005–2009 15 223 73480 21374 112 161 104 046 10904 337188
1995–2009 43 996 194803 49333 305 723 286 173 25874 905902
Denmark
1995–1999 2690 11195 5827 16 919 17 202 3182 57015
2000–2004 2521 11986 6407 18 664 19 323 3104 62005
2005–2009 2803 13487 7535 20 796 22 610 3042 70273
1995–2009 8014 36668 19769 56 379 59 135 9328 189293
England
1995–1999 38 477 91784 41547 143 113 153 356 24771 493048
2000–2004 34 795 96411 43872 144 621 170 152 25955 515806
2005–2009 30 693 108276 47620 155 612 184 247 26336 552784
2010–2012 16 953 70283 31063 101 539 116 315 16194 352347
1995–2012 120 918 366754 164102 544 885 624 070 93256 1 913985
Norway
1995–1999 3324 10101 5035 9466 11 647 2497 42070
2000–2004 2881 11268 5377 10 881 13 339 2627 46373
2005–2009 2560 12440 5428 12 398 13 665 2536 49027
1995–2009 8765 33809 15840 32 745 38 651 7660 137470
Sweden
1995–1999 5760 15658 9209 13 678 27 653 4486 76444
2000–2004 5097 16570 9843 15 491 30 760 4376 82137
2005–2009 4463 18494 10397 17 575 31 755 4137 86821
1995–2009 15 320 50722 29449 46 744 90 168 12999 245402
Total
1995–2012 220 834 797534 322645 1094 501 1246 830 166016 3 848360
aIncludes rectosigmoid junction.
bIncludes anus and anal canal.
cExcludes trachea.
dIncludes fallopian tube, uterine ligaments, other and unspecified female organs, peritoneum and retroperitoneum.
Numbers of patients from other countries are equal to those in the CONCORD-2 study. The number of patients in England differs from the number in England in CONCORD-2 even for
comparable calendar periods because they are from a more up-to-date extract from a live data set.
1995
Australia
Canada
Denmark
Norway
Sweden
England
England
Office for
National
Statistics
CONCORD-2
study
1996 1997 1998 1999 20012000 2002 2003
Year of diagnosis
2004 2005 2006 2007 2008 2009 2010 2011 2012
Figure 1. Data sources and periods of diagnosis. The data in our study originated either from the CONCORD-2 study or from the Office for
National Statistics. Patients from England were grouped based on their date of diagnosis both by calendar periods of the CONCORD-2 study
(for comparability with the other countries) and by year (to allow analysis of yearly changes).
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Finally, we evaluated the year-on-year trend in England up to
2012, examining whether there had been any acceleration in
improvement in survival in more recent years. Using the year-on-
year estimates for England for patients diagnosed during 1995–
2012, we calculated the annual change in survival during the
periods 1995–1999, 2000–2004, 2005–2009 and 2010–2012. This
was the total percentage change in survival (e.g., the arithmetic
difference between survival in 1995 and 1999) divided by the
number of annual increments (e.g., the period 1995–1999 includes
5 years, but four annual increments).
We identified a panel of 57 clinicians with expertise in one of
the six cancers, using purposive sampling of the international
clinical networks of senior colleagues in cancer registries and
research institutions, ensuring a roughly balanced distribution by
country and cancer. We used the Delphi approach to establish
consensus of opinion between participants (Dalkey and Helmer,
1963; Hsu and Sandford, 2007). Clinicians were first invited to
respond to a semi-structured questionnaire before seeing the
results of the survival analyses, to elicit their perceptions of how
and why survival at the population level might have changed in
their country during 1995–2009. We then distributed the survival
analyses and the broad hypotheses arising from the questionnaires,
and we conducted in-depth interviews (face to face and by
telephone) with individual clinicians. We received responses from
25 clinicians (including 16 questionnaires and 16 interviews), fairly
representative of cancers and countries.
RESULTS
Years of diagnosis 1995–2009. Net survival was highest for
patients diagnosed with breast cancer, in the range 94–97% 1 year
after diagnosis and 81–86% at 5 years for those diagnosed in 2005–
2009. Survival was lowest from lung cancer, in the range 31–42% at
1 year and 10–17% at 5 years in 2005–2009 (Tables 2 and 3).
One- and five-year survival from the gastrointestinal cancers
was highest in Australia, and for the gynaecological cancers
survival was highest in Australia, Norway and Sweden. Lung
Table 2. Age-standardised 1-year net survival with 95% confidence intervals for adults (aged 15–99 years) by calendar period of
diagnosis, country and cancer site, and 1995–2009 survival improvement in England minus survival improvement in other
countries
1995–1999 2000–2004 2005–2009 2010–2012
1995–2009 improvement in
England minus 1995–2009
improvement in other country
Stomach
Australia 50.4 (49.3, 51.5) 53.0 (52.0, 54.1) 55.0 (53.8, 56.2) 3.5 (1.6, 5.3)
Canada 43.5 (42.6, 44.3) 45.8 (45.0, 46.7) 48.0 (47.2, 48.8) 3.5 (2.1, 5.0)
Denmark 34.8 (32.9, 36.7) 36.0 (34.0, 37.9) 42.5 (40.7, 44.4) 0.3 (2.5, 3.1)
England 35.4 (34.9, 35.9) 39.8 (39.3, 40.4) 43.5 (42.8, 44.1) 47.1 (46.3, 47.9)
Norway 42.5 (40.6, 44.4) 46.2 (44.2, 48.2) 49.3 (47.2, 51.4) 1.3 (1.7, 4.2)
Sweden 42.6 (41.2, 44.0) 44.6 (43.1, 46.1) 48.6 (47.0, 50.2) 2.1 (0.2, 4.3)
Colon
Australia 79.2 (78.7, 79.6) 81.7 (81.3, 82.1) 84.3 (83.9, 84.7) 0.0 (0.8, 0.7)
Canada 76.4 (76.0, 76.8) 79.2 (78.9, 79.6) 81.4 (81.1, 81.7) 0.0 (0.6, 0.7)
Denmark 69.5 (68.6, 70.4) 71.6 (70.7, 72.4) 75.2 (74.4, 76.0) 0.7 (2.0, 0.6)
England 68.7 (68.4, 69.0) 71.1 (70.8, 71.4) 73.7 (73.5, 74.0) 77.2 (76.8, 77.5)
Norway 76.0 (75.1, 76.9) 77.0 (76.1, 77.8) 79.7 (78.9, 80.4) 1.4 (0.1, 2.7)
Sweden 77.1 (76.3, 77.8) 79.3 (78.6, 80.0) 82.1 (81.5, 82.8) 0.0 (1.1, 1.0)
Rectum
Australia 83.2 (82.5, 83.8) 85.6 (85.0, 86.2) 87.2 (86.6, 87.8) 2.0 (0.9, 3.1)
Canada 81.4 (80.7, 82.2) 82.8 (82.2, 83.5) 84.9 (84.4, 85.4) 2.5 (1.4, 3.6)
Denmark 73.9 (72.7, 75.1) 78.1 (77.0, 79.1) 81.8 (80.9, 82.7) 1.9 (3.5, 0.3)
England 74.3 (73.9, 74.8) 77.8 (77.4, 78.3) 80.3 (79.9, 80.7) 84.5 (84.0, 84.9)
Norway 81.1 (79.9, 82.2) 82.2 (81.1, 83.2) 85.7 (84.7, 86.6) 1.4 (0.2, 3.0)
Sweden 81.9 (81.0, 82.7) 83.2 (82.4, 84.0) 84.7 (84.0, 85.5) 3.2 (1.9, 4.4)
Lung
Australia 38.4 (37.8, 38.9) 40.8 (40.3, 41.4) 42.3 (41.7, 42.8) 3.0 (2.1, 3.8)
Canada 36.7 (36.3, 37.0) 37.8 (37.5, 38.1) 39.8 (39.4, 40.1) 3.8 (3.2, 4.4)
Denmark 25.5 (24.8, 26.2) 31.5 (30.8, 32.2) 35.3 (34.6, 36.1) 2.9 (4.0, 1.9)
England 24.5 (24.2, 24.7) 28.3 (28.0, 28.5) 31.3 (31.1, 31.6) 36.7 (36.4, 37.0)
Norway 31.2 (30.2, 32.1) 32.9 (31.9, 33.9) 39.4 (38.4, 40.3) 1.4 (2.8, 0.1)
Sweden 33.9 (33.1, 34.8) 37.1 (36.3, 37.9) 40.8 (40.0, 41.6) 0.0 (1.2, 1.2)
Breast
Australia 95.7 (95.5, 96.0) 96.4 (96.2, 96.7) 96.6 (96.4, 96.9) 3.1 (2.6, 3.6)
Canada 94.9 (94.7, 95.1) 95.4 (95.3, 95.6) 95.6 (95.4, 95.8) 3.3 (2.9, 3.7)
Denmark 92.4 (91.9, 92.9) 94.1 (93.7, 94.6) 95.2 (94.8, 95.7) 1.2 (0.5, 1.9)
England 90.2 (90.0, 90.4) 92.6 (92.4, 92.8) 94.2 (94.1, 94.4) 95.7 (95.5, 95.9)
Norway 95.0 (94.5, 95.6) 95.7 (95.2, 96.2) 96.4 (95.9, 96.9) 2.6 (1.9, 3.4)
Sweden 96.0 (95.7, 96.3) 96.7 (96.4, 97.0) 97.1 (96.8, 97.4) 2.9 (2.4, 3.4)
Ovary
Australia 70.9 (69.7, 72.1) 73.6 (72.4, 74.7) 74.8 (73.6, 75.9) 2.9 (1.0, 4.9)
Canada 68.2 (67.1, 69.3) 69.3 (68.3, 70.3) 71.6 (70.7, 72.5) 3.5 (1.7, 5.2)
Denmark 61.7 (60.0, 63.3) 66.2 (64.5, 67.8) 70.7 (69.1, 72.3) 2.2 (4.7, 0.4)
England 57.3 (56.5, 58.0) 60.7 (60.0, 61.4) 64.1 (63.5, 64.8) 68.1 (67.2, 68.9)
Norway 69.1 (67.3, 70.8) 74.1 (72.4, 75.7) 74.7 (73.1, 76.4) 1.2 (1.4, 3.8)
Sweden 75.6 (74.3, 76.8) 77.2 (76.0, 78.5) 79.5 (78.3, 80.8) 2.9 (0.8, 4.9)
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cancer survival was highest in Australia, Canada and Sweden.
Survival point estimates were slightly lower in England than in
Denmark for all cancer sites at 1 and 5 years after diagnosis, with
the exceptions of stomach cancer (whole study period) and rectal
cancer (in 1995–1999).
There was improvement in 1- and 5-year survival over time for
all cancers and in all countries. The mean improvement in 1-year
survival among the six participating countries between 1995–1999
and 2005–2009 was 2% for breast cancer, and 5–7% for the other
five cancers. For 5-year survival, the mean improvement was 6–7%
for colon and rectal cancers, and 3-4% for the other four cancers.
One- and five-year survival were lowest in England and
Denmark for all cancers, and, with few exceptions, remained so
throughout 1995–2009 (Figure 2). The exceptions were that by
2005–2009 there was no evidence of difference between Denmark
and Canada in 1-year survival from breast and ovarian cancers,
and by that time, there was also no evidence of difference in 5-year
survival from ovarian cancer between Denmark and either
Australia or Canada. By contrast, there is evidence that survival
in England during 2005–2009 remained lower than in Australia,
Canada, Norway and Sweden for all six cancers.
Calendar period of diagnosis 2010–2012 in England vs 2005–
2009 in other countries. Survival for patients diagnosed with one
of these six cancers in England in 2010–2012 generally remained
lower than for the equivalent patients diagnosed in 2005–2009 in
Australia, Canada, Norway and Sweden (Tables 2 and 3). The
exceptions were that there was no evidence of difference in 1-year
survival for patients diagnosed with a cancer of the stomach,
rectum or breast in 2010–2012 in England compared with patients
diagnosed with one of those cancers in 2005–2009 in Canada.
Similarly, there was no evidence of difference in 1-year survival for
patients diagnosed with stomach cancer in 2010–2012 in England
compared with patients diagnosed in 2005–2009 in Norway or
Sweden, or for rectal cancer patients in England compared with
Sweden at 1 or 5 years after diagnosis.
Trends in cancer survival in England compared with Australia,
Canada, Norway and Sweden, 1995–2009. For patients
Table 3. Age-standardised 5-year net survival with 95% confidence intervals for adults (aged 15–99 years) by calendar period of
diagnosis, country and cancer site, and 1995–2009 survival improvement in England minus survival improvement in other countries
1995–1999 2000–2004 2005–2009 2010–2012
1995–2009 improvement in
England minus 1995–2009
improvement in other country
Stomach
Australia 25.9 (24.8, 27.0) 27.8 (26.8, 28.9) 27.9 (26.7, 29.0) 1.9 (0.1, 3.6)
Canada 21.1 (20.4, 21.9) 23.1 (22.3, 23.9) 24.8 (24.0, 25.6) 0.2 (1.1, 1.5)
Denmark 13.8 (12.3, 15.3) 15.3 (13.7, 16.9) 17.9 (16.2, 19.5) 0.2 (2.6, 2.1)
England 14.3 (13.9, 14.7) 16.3 (15.9, 16.8) 18.2 (17.6, 18.7) 20.7 (19.9, 21.4)
Norway 21.1 (19.4, 22.9) 22.0 (20.2, 23.9) 24.1 (22.1, 26.1) 0.9 (1.9, 3.6)
Sweden 21.2 (19.9, 22.5) 21.0 (19.6, 22.3) 23.2 (21.7, 24.6) 1.9 (0.2, 3.9)
Colon
Australia 60.3 (59.7, 61.0) 63.1 (62.5, 63.7) 64.2 (63.6, 64.8) 2.3 (1.2, 3.3)
Canada 56.8 (56.3, 57.3) 60.1 (59.6, 60.6) 62.8 (62.4, 63.3) 0.2 (0.7, 1.1)
Denmark 48.2 (47.1, 49.4) 52.1 (50.9, 53.2) 55.9 (54.8, 57.0) 1.5 (3.2, 0.2)
England 47.5 (47.1, 48.0) 50.9 (50.5, 51.3) 53.7 (53.3, 54.1) 58.7 (58.3, 59.2)
Norway 55.9 (54.6, 57.2) 58.4 (57.2, 59.6) 61.8 (60.6, 62.9) 0.3 (1.5, 2.1)
Sweden 55.4 (54.4, 56.5) 59.4 (58.5, 60.4) 62.5 (61.6, 63.5) 0.9 (2.4, 0.6)
Rectum
Australia 59.9 (58.9, 61.0) 63.8 (62.9, 64.7) 64.2 (63.3, 65.1) 3.2 (1.6, 4.8)
Canada 56.5 (55.4, 57.5) 60.5 (59.6, 61.5) 62.8 (61.9, 63.7) 1.2 (0.4, 2.8)
Denmark 47.6 (46.0, 49.2) 53.8 (52.2, 55.3) 58.4 (56.9, 59.8) 3.3 (5.6, 1.0)
England 48.8 (48.1, 49.4) 53.8 (53.3, 54.4) 56.3 (55.7, 56.8) 61.0 (60.3, 61.8)
Norway 57.8 (56.1, 59.5) 61.7 (60.1, 63.3) 64.6 (63.0, 66.2) 0.7 (1.8, 3.2)
Sweden 57.9 (56.6, 59.2) 59.6 (58.4, 60.8) 62.0 (60.9, 63.2) 3.4 (1.5, 5.3)
Lung
Australia 13.7 (13.3, 14.2) 14.8 (14.4, 15.2) 15.0 (14.6, 15.5) 1.1 (0.4, 1.8)
Canada 15.1 (14.8, 15.3) 15.6 (15.4, 15.9) 17.3 (17.1, 17.6) 0.2 (0.2, 0.7)
Denmark 8.0 (7.5, 8.5) 9.6 (9.1, 10.1) 11.3 (10.7, 11.9) 0.9 (1.7, 0.0)
England 7.0 (6.9, 7.2) 8.4 (8.2, 8.6) 9.5 (9.3, 9.7) 12.7 (12.4, 13.0)
Norway 10.7 (10.0, 11.5) 11.7 (10.9, 12.4) 15.0 (14.1, 15.8) 1.9 (3.0, 0.7)
Sweden 12.2 (11.6, 12.9) 13.3 (12.7, 14.0) 15.6 (14.9, 16.4) 1.0 (2.0, 0.1)
Breast
Australia 84.6 (84.0, 85.2) 86.4 (85.9, 86.9) 86.2 (85.6, 86.8) 5.5 (4.6, 6.5)
Canada 83.7 (83.3, 84.1) 85.3 (84.9, 85.7) 85.8 (85.5, 86.2) 5.0 (4.3, 5.8)
Denmark 75.8 (74.8, 76.8) 80.7 (79.8, 81.6) 82.0 (81.1, 82.9) 0.9 (0.5, 2.4)
England 73.9 (73.6, 74.3) 78.6 (78.3, 79.0) 81.1 (80.7, 81.4) 84.0 (83.6, 84.4)
Norway 81.5 (80.3, 82.6) 84.1 (83.0, 85.1) 85.9 (84.9, 87.0) 2.7 (1.1, 4.4)
Sweden 83.8 (83.1, 84.5) 85.6 (84.9, 86.3) 86.2 (85.5, 86.9) 4.7 (3.6, 5.8)
Ovary
Australia 36.1 (34.8, 37.4) 37.0 (35.7, 38.3) 37.5 (36.2, 38.8) 1.9 (0.2, 4.1)
Canada 36.5 (35.3, 37.7) 35.5 (34.4, 36.6) 37.5 (36.3, 38.6) 2.3 (0.4, 4.3)
Denmark 31.2 (29.5, 33.0) 33.2 (31.5, 34.9) 37.3 (35.4, 39.2) 2.8 (5.6, 0.1)
England 28.2 (27.4, 29.0) 29.6 (28.9, 30.4) 31.5 (30.8, 32.3) 35.2 (34.2, 36.2)
Norway 36.7 (34.7, 38.8) 40.2 (38.2, 42.3) 40.3 (38.3, 42.4) 0.3 (3.4, 2.9)
Sweden 40.8 (39.2, 42.4) 42.8 (41.2, 44.4) 43.5 (41.9, 45.1) 0.6 (1.9, 3.2)
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diagnosed in 1995–1999, the average gap in 1-year survival
between England and the four leading countries was 5–14%; by
2005–2009 it was 2–11%. Equivalent figures for 5-year survival
were 6–10% and 5–9%, respectively. Although England had not
closed the gap in survival with Australia, Canada, Norway or
Sweden by 2005–2009, the difference between the improvement in
England and the improvement in each other country (improve-
ment in England minus other country improvement) was generally
positive (Tables 2 and 3). There was evidence at the 5% level of
statistical significance that the improvement in 1-year survival
between 1995–1999 and 2005–2009 in England was greater than in
Australia and Canada for patients diagnosed with any of these
cancers except for cancer of the colon. In addition, there was
evidence that the improvement was greater for 1-year survival
compared with Norway for colon and breast cancers, and
compared with Sweden for rectal, breast and ovarian cancers.
There was also evidence that the improvement in 5-year survival
between 1995–1999 and 2005–2009 was greater in England than in
Australia for all but ovarian cancer. In addition, the improvement
in 5-year survival from rectal cancer was greater than in Sweden,
and for ovarian cancer compared with Canada. The improvement
in 1- and 5-year survival from breast cancer was greater than in all
four leading countries.
Trends in cancer survival in England compared with Denmark,
1995–2009. Survival in Denmark was generally as low as in
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Figure 2. Trends in 1- and 5-year net survival in Australia (A), Canada (C), Denmark (D), England (E), Norway (N) and Sweden (S) by period of
diagnosis. Estimates of net survival are presented for the calendar periods of diagnosis 1995–1999, 2000–2004 and 2005–2009. Simple linear
regression lines are presented for each combination of country and cancer using data from these three periods, to indicate the average change in
survival. An estimate of net survival for England only is also presented for the calendar period of diagnosis 2010–2012.
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England in 1995–1999, though significantly slightly higher for
lung, breast and ovarian cancer at 1 and 5 years (Tables 2 and 3,
Figure 2). The difference in the improvement in England compared
with the improvement in Denmark between 1995–1999 and 2005–
2009 was however generally negative, that is, survival improved
more in Denmark than in England for these cancers, except for
breast cancer at 1 and 5 years, and stomach cancer at 1 year. There
is evidence at the 5% level of statistical significance that survival
improved more in Denmark than in England at 1 and 5 years for
rectal cancer, and at 1 year for lung cancer. For patients diagnosed
in 2005–2009, survival was lower in England than in Denmark for
colon and rectal cancers at 1 and 5 years, as well as remaining
lower for lung, breast (1-year survival only) and ovarian cancers.
One-year survival from lung cancer in Denmark was 1.1% (0.3–
1.8%) higher than in England in 1995–1999, but by 2005–2009,
survival was 4.0% (3.2–4.8%) higher in Denmark (arithmetic gap in
1- and 5-year survival: Supplementary Webtables 7 and 8).
Survival trends in England during 1995–2012. The year-on-year
trends in survival in England during 1995–2012 show a period of
relative improvement in net survival in the late 1990s, followed by
some years of stability in the early 2000s (Figure 3). During 2005–
2009, survival again improved more quickly particularly for 1- and
5-year survival from colon, rectal and ovarian cancers. For stomach
and lung cancers, that pattern can be seen for 1-year survival but
less so for 5-year survival, which showed rather little annual
improvement before 2005, followed by steady improvement,
especially for lung cancer. Breast cancer is the exception: the
biggest annual improvements in 1- and 5-year survival occurred in
the late 1990s, with smaller but steady improvements since then,
particularly for 5-year survival. For lung cancer, 1-year survival has
improved more rapidly since 2007/2008, with the annual
improvement peaking at 2.2% per annum for patients diagnosed
in 2010–2012. Five-year lung cancer survival also improved, but
more slowly, at 1.1% per annum from 2010.
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Figure 3. Trends in 1- and 5-year net survival in England by year of diagnosis. Unfilled and filled markers represent estimates of 1- and 5-year net
survival, respectively. The average arithmetic improvement in survival between years is shown for the calendar periods 1995–1999, 2000–2004,
2005–2009 and 2010–2013 above the trends.
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DISCUSSION
Despite steady improvement in survival from stomach, colon,
rectal, lung, breast and ovarian cancers in England over the past
two decades, survival remained lower than in Australia, Canada,
Norway and Sweden for patients diagnosed in 2005–2009, and
typically also for patients diagnosed in 2010–2012 in England
compared with those diagnosed in 2005–2009 elsewhere. The
improvement in survival between 1995–1999 and 2005–2009 was
sometimes larger than in the leading countries, particularly in
comparison with Australia, Canada and Sweden, leading to some
narrowing of the international cancer survival gap. As in England,
Denmark also had relatively low survival in comparison to the
other four countries in 1995–1999, and cancer control has similarly
engendered considerable public debate in that country. Survival
generally improved more in Denmark than in England between
1995–1999 and 2005–2009, particularly for lung and rectal cancers.
Since 2009, improvement in survival from lung cancer has
accelerated in England, and there has also been slight acceleration
for ovarian, breast and rectal cancers.
Explaining trends in England. In England, survival generally rose
in the late 1990s, followed by a relatively stable period in the early
2000s, after which it improved more quickly, apart from for breast
cancer where the greatest gains were seen in the 1990s followed by
continued but smaller annual increments throughout the 2000s.
Relative stability in survival in the early 2000s was previously
identified in an evaluation of the impact of the NHS Cancer Plan
for England (Rachet et al, 2009). That strategy, launched in
September 2000, proposed to inject an additional d570 million into
cancer services by 2003–2004 to improve prevention, screening,
diagnosis and treatment; it established Cancer Networks to oversee
specialisation and centralisation of cancer care, following the
earlier recommendations of Calman and Hine (Department of
Health, 2000). Rachet et al (2009) found that despite the increased
investment in services, survival in England did not increase during
2001–2003 as much as in Wales, which had not yet implemented a
national cancer plan. These trends were reversed during 2004–
2006, once the new structures and relationships in England were
properly established (House of Commons Committee of Public
Accounts, 2006).
In order to fully evaluate the impact of the NHS Cancer Plan on
survival, the need for data up to the end of 2009 was noted (Rachet
et al, 2009). We present those data here, showing that accelerating
improvement in survival in England did arise in the mid-2000s.
There is consensus among clinicians and auditors that this
improvement can be attributed to the national reforms launched
during 1995–2000 and their continuing momentum throughout
the 2000s, manifest in two revisions to the national strategy and
growing emphasis on outcomes monitoring (Department of
Health, 2007, 2011). Increased investment, specialisation and
centralisation, greater use of MDTs, target-monitoring and
performance review are described as key drivers of change in
clinical culture and practice, and as the main reasons for improved
cancer patient outcomes in England in the 2000s (House of
Commons Committee of Public Accounts, 2011).
Treatment in high-volume, specialised centres by sub-specialists
with high caseloads is associated with provision of more
appropriate treatment and better patient outcomes (Birkmeyer
et al, 2003; Hannan et al, 2002; Meyer, 2005), and the drive to
increase such centralisation had an impact in England. For
example, during 2000–2009, the percentage of women with
ovarian cancer receiving surgery who were treated in a specialist
trust rose from 43 to 76%, and the number treated by a specialist
surgeon (caseload of 418 patients per year) rose from 20 to 55%
(Butler et al, 2015). For lung cancer, the number of specialist
thoracic surgeons doubled from 44 in 2006 to 84 whole-time
equivalent (WTE) in 2014 (personal communication: Sridhar
Rathinam, Workforce Lead for the Society of Cardiothoracic
Surgeons, 28 April 2015), meaning that more resections were
performed by lung specialists, rather than cardiothoracic general-
ists as in the past (Page et al, 2011). The total number of resections
for lung cancer carried out in the United Kingdom and Ireland each
year has risen from c.3000 in 2001–2002 to c.5000 by 2009–2010
(Page et al, 2011), and to over 6000 by 2011–2012 (Society for
Cardiothoracic Surgery in Great Britain and Ireland, undated), and
the overall percentage of patients resected in England and Wales
rose from 9 to 15% during 2005–2013 (Health and Social Care
Information Centre, 2014; The NHS Information Centre, 2006). At
the same time, increased specialisation has meant that surgeons are
more willing to operate on patients with higher risks of poor
outcomes, such as those with co-morbidities or older patients, so, for
example, there has been a particularly large increase in the resection
of lung cancer patients older than 65 years (Riaz et al, 2012).
Specialisation and improved diagnostic investigations have
led to better targeting of treatment and lower postoperative
mortality. For example, 30-day mortality following gastrectomy
was 4.5% in 2007–2009 in England (Cromwell et al, 2010),
compared with 12.0% in 24 hospitals in England and Wales in
1999–2002 (McCulloch et al, 2003). It is likely this is partly due to
the increase in the percentage of specialist centres that have three
or more specialist surgeons (as per the guidelines) from 53% in
2007 to 95% in 2012, and partly because by 2012 nearly all stomach
cancer patients eligible for curative treatment were seen by a
specialist MDT (Groene et al, 2014). Thirty-day postoperative
mortality from colorectal cancer also declined from 6.8% in 1998 to
5.8% in 2006, with the biggest decline occurring in 2005–2006
(Morris et al, 2011).
Reforms in cancer services in England have contributed to
improved survival over the past two decades for these six cancers,
but these changes did not necessarily lead to a closed gap in
survival between England and other countries, because despite
relative improvement over time, there may remain comparative
shortfalls in provision, partly due to the implementation of parallel
reforms elsewhere.
Comparison of cancer control reforms. Both Norway and
Denmark had launched national cancer plans by 2000, which
similarly emphasised centralisation, specialisation and improved
patient pathways (Danish National Board of Health, 2000;
Norwegian Official Reports, 1997). The early EUROCARE studies
had a similar effect in Denmark as they did in England, showing
lower survival than in comparable European nations, and
prompting public and parliamentary scrutiny of Danish cancer
control (Olesen et al, 2009). The Danish cancer plans that were
published throughout the 2000s had strong political support and a
wide mandate, leading to rapid implementation. Since 2001,
surgery for lung cancer has been concentrated from seven
departments to four (Starr et al, 2013), ovarian cancer surgery
was reduced from 47 departments to 8 during 2004–2007 (Ottesen
et al, 2009) and gastric cancer surgery was restricted from 37
departments to 4 university departments during 1999–2007
(Jensen et al, 2007; Jensen et al, 2010). There has also been
emphasis on centralisation for colorectal cancer surgery to a
greater degree than in England, although this could be because
hospitals in England generally treat a larger volume of patients
than in Denmark. While in England most hospital trusts conduct
surgery for colorectal cancer, in Denmark the number of
departments performing surgery for colon and rectal cancers
reduced from 38 to 15 during 2003–2012 (Lykke et al, 2013).
One- and five-year survival improved more in Denmark than
in England during 1995–1999 to 2005–2009 for all but stomach
(1-year) and breast cancer (1- and 5-year), with statistical evidence
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that improvement was greater in Denmark for rectal (1- and 5-year
survival) and lung cancer (1-year). This could be because of more
comprehensive reform in Denmark or because strategies were
better targeted. For example, both England and Denmark identified
improving early diagnosis as a priority (Olesen et al, 2009;
Richards, 2009), and this may have had more impact in Denmark,
where the stage distribution was initially more adverse than in
England for some cancers (Maringe et al, 2012; Maringe et al,
2013). Acknowledging the positive impact of these reforms, health
policymakers and clinicians in Norway and Sweden are increas-
ingly influenced by Denmark in designing their own cancer
strategies, as shown by recent policy in both of those countries to
emulate the Danish model of standardised patient pathways
(Probst et al, 2012).
Evidence that survival in England improved faster than in other
countries during 1995–2009 was strongest in relation to Australia,
Canada and Sweden. This could be explained by a partial ‘ceiling
effect’ in those countries, given that they generally had the highest
survival at the beginning of the study period. Alternatively, more
regionalised health systems in those three countries might have
limited the efficacy of national cancer control strategy and the
power of national guidelines. While Denmark, England and
Norway all introduced national cancer plans by 2000, in the
federal countries of Australia and Canada the first provincial
cancer plans were launched in the mid-2000s (Cancer Care
Ontario, 2004; Cancer Institute New South Wales, 2004), and it
was not until 2006–2007 that national oversight bodies were
founded to coordinate cancer policy in the various regions. The
Canadian Strategy for Cancer Control was published in 2006,
leading to the founding of the Canadian Partnership Against
Cancer in 2007 (Canadian Strategy for Cancer Control Governing
Council, 2006). Cancer Australia was founded in 2006 and has
issued a national cancer strategy for 2014–2019. Federalism as well
as the remoteness of some rural communities in these countries
may pose a larger challenge to the implementation of national
standards than in the geographically smaller European countries,
possibly explaining the slightly flatter trends in survival for some
cancers, such as ovarian (5-year) and lung, despite overall higher
survival (Hegney et al, 2005; Tracey et al, 2014). The first Swedish
National Cancer Strategy was launched in 2009, and it is as yet
unclear how successful it has been in influencing coordinated
policy between the Regional Health Boards.
Colorectal oncologists in Sweden and Norway, and lung cancer
specialists in England, identified the creation of national quality
registries as having been instrumental in the drive towards better
care and in improved outcomes in those countries. Population-
based quality registries for rectal cancer were established in
Norway and Sweden in 1993 and 1995, respectively, to monitor the
rollout of novel surgical techniques and the impact on recurrence
and survival (Påhlman et al, 2007; Wibe et al, 2002). The registries
were expanded to include colon cancer in 2007 (Guren et al, 2015;
Kodeda et al, 2013). Similarly, in England, the national lung cancer
audit was initiated in 2004 and now includes all lung cancer
patients referred to an MDT in England (Khakwani et al, 2013a;
Rich et al, 2011c). Information from these quality registries is
regularly fed back to cancer centres and hospital trusts, through
public reports, oral presentations and meetings.
Studies have shown that the availability of these data has
improved standards, persuading smaller centres to stop operating
or to recruit specialist colorectal surgeons in Sweden and Norway,
and leading to an increase in histological confirmation for lung
cancer in England (Beckett et al, 2012; Påhlman et al, 2007).
The data sets have spawned a wealth of research that should lead to
better-targeted cancer-control policies (Dahlberg et al, 1998; Guren
et al, 2015; Hansen et al, 2007; Rich et al, 2011a, b), and they
have been acknowledged as setting the standard for quality
registration in Europe (Blum et al, 2014). Other national audits are
increasingly available in England, and if these data streams
continue to be accessible for research and local-level benchmark-
ing, the prospects for continued harmonisation towards best
practice are strong.
Innovations in diagnosis and treatment. In addition to structural
reforms, investment and monitoring of outcomes, improvements
in survival have also been driven by innovations in diagnostics and
treatment over the past two decades. Broadly speaking, innovations
have been universally implemented in all six countries, but there
are important differences in the timing and degree of provision,
which could have contributed to differential survival in the 2000s.
In the case of colorectal cancer, major innovations that
could have influenced population-based survival during 1995–
2009 include improvements in preoperative staging through
advances in high-resolution radiology, the uptake of total
mesorectal excision (TME) surgery, the increased use of pre-
operative (chemo)radiotherapy and the treatment of metastatic
disease. There is evidence that implementation of some of these
innovations was slower in England than elsewhere. The use of
advanced imaging tools for rectal cancer staging (MRI or, in
Australia, positron emission tomography (PET) combined with
computed tomography (CT)) has increased in most of these
countries since the late 1990s. By 2011–2012, 86% of rectal cancer
patients in England had an MRI before treatment (Scott et al, 2013:
p. 69), compared with 97% of patients in Sweden receiving MRI
plus investigation for metastases in the liver and lungs in 2013
(Regionalt Cancercentrum Norr, 2014). TME was pioneered in
England in the early 1980s, and shown to reduce locoregional
recurrence for rectal cancer. However, TME only became common
practice in England much later than in the Nordic countries, where
more effective efforts were made to ensure and monitor
implementation (e.g., through the Norwegian Rectal Cancer
Project and its equivalent in Sweden from 1993/1994) (Guren
et al, 2015; Martling et al, 2005; Richards, 2009; Wibe et al, 2002).
Although surgery has improved in England, the resection rate
remains lower than it was in the early 2000s in some other
countries. For example, we estimated that 32% of rectal cancer
patients diagnosed in England in 2012–2013 (Scott et al, 2014) had
an anterior resection compared with 45% in Sweden in 1995–2004
(Jung et al 2009) (details of calculation available on request).
Similarly, for stomach cancer, while in 2000–2005 in Ontario 45%
of patients were treated with curative intent, in 2011–2012 in
England 38% received surgery (Coburn et al, 2010; Taylor et al,
2014: p. 5).
In relation to lung cancer, although there has been a significant
increase in resection rate and resection numbers in England, and
an increase in the proportion of patients seen by specialists, there
remains scope for improvement. The number of thoracic surgeons
almost doubled to 84 WTE during 2006–2014 (personal commu-
nication: Sridhar Rathinam, Workforce Lead for the Society of
Cardiothoracic Surgeons, 28 April 2015), but with over 30 000 lung
cancer patients diagnosed each year, the number remains relatively
small. There is evidence that diagnostic procedures may be less
aggressive in England than elsewhere. The National Lung Cancer
Audit in England set a target (which has been met since 2009) of
75% for pathological confirmation of lung cancer (Health and
Social Care Information Centre, 2012). In contrast in Sweden, 95%
of lung cancer patients diagnosed during 2002–2010 had their
tumour verified by cytology or histology (Regionalt Cancercentrum
Uppsala O¨rebro, 2012: p. 10, Table 3). There remains wide
variation in the proportion of pathological confirmation by age
group and region in England: for patients aged over 75, this is just
50% (Khakwani et al, 2013b). In a pan-European study on the
quality of lung cancer care, only 4% of participating hospitals in
England reported a histological confirmation rate higher
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than 90%, compared with 87% of Danish participating hospitals
(Blum et al, 2014).
These contrasts may reflect differences in clinical guidelines or
access to diagnostic investigations. PET scan, usually in combina-
tion with CT, is important in the assessment of the likelihood of
mediastinal and/or extra-thoracic metastasis that would contra-
indicate treatment with curative intent. A PET–CT positive result
may represent malignant infiltration but may also be a false
positive for benign inflammation, therefore, histological investiga-
tion (biopsy by ultrasound-guided needle aspiration or mediasti-
noscopy) may be needed to confirm malignant disease (Schmidt-
Hansen et al, 2014). In England, PET–CT is currently only
recommended for patients potentially suitable for treatment with
curative intent, while in Ontario PET–CT is recommended, if
available, for all patients after a pathological diagnosis of NSCLC
(Cancer Care Ontario, 2012). According to English guidelines,
histological investigation of mediastinal lymph nodes is only
indicated as an alternative to PET–CT (National Institute for
Health and Clinical Excellence (NICE), 2011), whereas in Ontario
and Denmark histological confirmation is recommended together
with PET–CT, for all patients with centrally located tumours
or with suspected mediastinal node involvement (Dansk Lunge
Cancer Gruppe, 2014; Darling et al, 2010).
The international trend in breast cancer survival is unusual, in that
the largest improvement in survival in all countries was experienced
in the 1990s, and the 2000s have been characterised by a closing
survival gap between England and Denmark and the four leading
countries. This is probably because although there have been
continued improvements in breast cancer diagnosis and treatment
(including the introduction of targeted therapies, and improved usage
of antihormonal treatments and chemotherapy), major innovations
for breast cancer, such as adjuvant chemotherapy and tamoxifen,
were introduced in the 1970s–1980s, and population screening had
also been introduced in England before our study period.
Furthermore, improvements in service organisation (e.g., use of
MDTs and issuance of clinical guidelines) occurred earlier than for
the other five cancers in England. By 1995, 1-year survival from
breast cancer was already 95% or above in the four leading countries,
and it is likely that the closing international survival gap arises mainly
because of a ‘ceiling effect’ elsewhere.
Recent trends and future prospects. There was an acceleration in
survival improvement in England in more recent years. The
average annual improvement in survival was higher in 2005–2009
than in 2000–2004 for the gastrointestinal, lung and ovarian
cancers, and higher in 2010–2012 than in 2005–2009 for rectal
and ovarian cancers at 1 year, and lung cancer at 1 and 5 years.
The recent acceleration in lung cancer survival improvement has
been especially large, and the improvement in 5-year survival since
2006 has particular significance given the relatively static trend
until then. This improvement coincides with the doubling of the
resection rate for lung cancer in recent years (Page et al, 2011).
It is unclear whether these trends represent further closing of
the international survival gap because data are not yet available for
the comparator countries. However, there are indications that
some novel therapies and approaches, which could have affected
recent survival trends in the six countries, have been implemented
later in England than elsewhere. For example, the introduction of
stereotactic body radiotherapy (SBRT) as an alternative to surgery
for early-stage lung cancer patients could have improved lung
cancer survival at the population level, given that it widens access
to treatment with curative intent to patients with contraindications
for surgery (Haasbeek et al, 2012). Data are not yet available on the
relative availability of SBRT in the six countries, but it was
pioneered in Sweden (Lax et al, 1994), it was indicated in clinical
guidelines in Denmark, Ontario and Sweden earlier than in
England, and it has been available in some Danish and Swedish
cancer centres from the early-mid-2000s (Jeppesen et al, 2013;
Louie et al, 2014). Similarly, it is unclear how far there is variation
between these countries in the implementation of ultra-radical
surgery for ovarian cancer, and in the introduction of perioperative
chemotherapy (Cunningham et al, 2006) and improvements in
palliative oncology for stomach cancer (Bang et al, 2010). The
international survival gap may narrow as England introduces
innovations that are already implemented in other countries,
or widen as such innovations become widespread in other
countries first.
Equally, there is potential for a widening survival gap if reforms
implemented earlier in England are now replicated elsewhere. For
example, a national bowel cancer screening programme was
introduced in England earlier than elsewhere (2006–2009), possibly
contributing to some of the recent improvement in bowel cancer
survival. However, all five other countries have now also
implemented either national or regional bowel screening pro-
grammes, which often cover a wider age range than in England.
Therefore, it is likely that if improvements in stage distribution or
survival were effected by screening in England, they will also soon be
effected elsewhere (Flitcroft et al, 2010; Zavoral et al, 2009).
Likewise, health system factors and national cancer policy were
instrumental in driving improvements in cancer outcomes in
England in the 2000s, but concerns have arisen about continuity of
those system-level effects following reforms implemented
since through the Health and Social Care Act 2012 (Cancer
Research UK, 2012; National Audit Office, 2015). Since April 2013,
commissioning services for cancer have been restructured,
changing from 152 Primary Care Trusts to 211 Clinical
Commissioning Groups; the 28 Cancer Networks, which worked
to ensure consistency and quality in cancer services for more than
a decade, have been disbanded, and key strategic policy posts
within the Department of Health have been changed to advisory
roles within NHS England, or dissolved. These reforms came at a
time of financial austerity: the health service is under pressure to
make unprecedented efficiency savings of d20 billion by 2014–
2015, and the average annual spend on cancer services per head of
the population fell by 3.4% in 2010–2011 (Cancer Research UK,
2012). Such financial restrictions compound existing lower levels of
cancer spending compared with other northwest European
countries (Luengo-Fernandez et al, 2013).
There is already evidence that cancer services have been
affected, with some performance targets having been missed for
the first time (e.g., the target of a maximum 62-day wait between
urgent GP referral and treatment for 85% of patients was not met
during 2014–2015) (NHS England, 2015). Furthermore, although
there is continued emphasis on outcomes monitoring in the
reformed NHS, and cancer intelligence continues to improve,
systems of formal accountability have been reshaped, implying
risks to the continued dissemination and use of this intelligence to
improve standards. This is compounded by increased restrictions
on data access for research due to rising sensitivity around patient
confidentiality (National Audit Office, 2015).
England’s future trajectory towards closing the international gap
in cancer survival is therefore uncertain, and continued interna-
tional cancer survival surveillance is needed to monitor on-going
progress. It will be important that such surveillance is age-specific,
given evidence of the particularly wide gap in survival for older
patients (Maringe et al, 2013; Walters et al, 2013)
CONCLUSION
One- and five-year survival from six common cancers in England
was lower than in Australia, Canada, Norway and Sweden in
2005–2009. By 2010-2012 1-year survival in England remained
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lower than in 2005–2009 in the four leading countries for three of
these cancers, and 5-year survival remained lower for five of these
cancers. During 1995–1999 to 2005–2009, improvement in 1-year
survival was generally higher in England than in Australia, Canada
or Sweden. For breast cancer, survival at both 1 and 5 years in
England improved more than in these countries or Norway. There
has been notable acceleration in improvement in survival from
lung cancer during 2010–2012, as well some acceleration for rectal
and ovarian cancers.
The improvement in survival in England was partly due to
innovations in diagnostics and treatment, although there is
evidence that novel therapies were often implemented more
quickly elsewhere. Other key drivers were strong strategic leader-
ship, increased investment, and the creation of more stable and
centralised commissioning structures to enhance observance of
national guidelines, as well as increased availability of data for
outcomes monitoring and local benchmarking. Survival in
Denmark was similarly lower than in the other four countries in
1995–1999, but it generally improved faster than in England over
the next decade, especially for rectal and lung cancers. This may be
ascribed to particularly effective centralisation, specialisation and
performance monitoring in Denmark in the 2000s.
In some instances, survival in England improved more than in
Australia, Canada, Norway or Sweden during the 2000s, but future
trends are uncertain in the context of health service reform and
efficiency savings. Committed investment in centralised, specia-
lised and accountable services for cancer patients will be essential
for continued progress against the international survival gap.
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